Background: Patients with temporomandibular joint disorders (TMD), reactive arthritis and rheumatoid arthritis often have combined etiology of hereditary and microenvironmental factors contributing to joint pain. Multiple clinical and animal studies indicate 'double-hit' inflammatory insults can cause chronic inflammation. The first inflammatory insult primes the immune system and subsequent insults elicit amplified responses. The present 'double hit' study produced a chronic orofacial pain model in mice with genetic deletion of both TNFa receptors (TNFR1/R2À/À), investigating the main nociceptive signalling pathways in comparisons to wild type mice. Methods: An initial inflammatory insult was given unilaterally into the temporomandibular joint (TMJ). Secondary hypersensitivity was tested on the skin over the TMJ throughout the experiment. Three weeks later after complete reversal of hypersensitivity, a second inflammatory insult was imposed on the colon. Pharmacological interventions were tested for efficacy after week 10 when hypersensitivity was chronic in TNFR1/ R2À/À mice. Serum cytokines were analysed at Days 1, 14, and Week 18. Results: The double hit insult produced chronic hypersensitivity continuing through the 4-month experimental timeline in the absence of TNFa signalling. P2X7 and NMDA receptor antagonists temporarily attenuated chronic hypersensitivity. Serum cytokine/chemokine analysis on Day 14 when CFA induced hypersensitivity was resolved identified increased levels of pro-inflammatory cytokines CCL2, CXCL9, CXCL10, RANTES and decreased levels of anti-inflammatory cytokines IL-1ra and IL-4 in TNFR1/R2À/À compared to WT mice. Conclusions: These data suggest a causal feed-forward signalling cascade of these little studied cytokines have the potential to cause recrudescence in this orofacial inflammatory pain model in the absence of TNFa signalling. Significance: Using a mouse model of chronic inflammatory temporomandibular joint disorder, we determined that absence of functional TNFR1/R2 induces aberrant inflammatory signalling caused by other increased pro-inflammatory and decreased anti-inflammatory cytokines that could serve as blood biomarkers and may predict disease progression.
Introduction
Similar to rheumatoid arthritis (RA) in other joints, temporomandibular joint disorders (TMD) are characterized by severe pain, but can also induce earaches, toothaches and chronic headaches (Buescher, 2007; Lupoli and Lockey, 2007; Schiffman et al., 2014) . As a major early onset pro-inflammatory cytokine, tumour necrosis factor alpha (TNFa) is released not only by immune cells but also by glia and neurons of the peripheral and central nervous system (Wagner and Myers, 1996; Schafers et al., 2003; Ohtori et al., 2004; Gao and Ji, 2010) . Similar to patients with RA, patients with inflammatory TMD also have elevated levels of TNFa in their temporomandibular joint (TMJ) synovial fluid concurrent with pain (Takahashi et al., 1998; Kaneyama et al., 2002; Kopp et al., 2005; Ahmed et al., 2015; Kellesarian et al., 2016) . A critical role is implicated for dysregulated TNFa and malfunctioning TNFa receptors, TNFR1 and TNFR2, in the pathogenesis of chronic pain in multifactorial diseases such as RA (Maini et al., 1993) . Many patients with RA have gene polymorphisms in TNFa and the TNFa receptor genes (Hughes et al., 2004; Glossop et al., 2005; Korczowska, 2014) . Patients with reactive arthritis and RA often have a combined aetiology of hereditary and microenvironmental factors such as altered microbial flora in the gastrointestinal system (Toivanen, 2003) . Bacterial degradation products, their cell walls and DNA, have been identified in synovial fluids from patients with TMD, RA, and reactive arthritis (Klineberg et al., 1998; Toivanen, 2001; Chen et al., 2002; Olsen-Bergem et al., 2016) . Multiple experimental studies have demonstrated dysregulated TNFa and malfunctioning TNFR1 and TNFR2 caused by inflammation (Peschon et al., 1998; Kagari et al., 2002; Choi et al., 2010) , or neuropathy (Sommer and Kress, 2004) , as well as by 'double-hit' inflammatory insults that can cause chronic inflammation not only in joints (Hains et al., 2010; Westlund et al., 2012; Traub et al., 2014) but also in other organs (Mariotti et al., 2002; Ilievski and Hirsch, 2010) . The first inflammatory insult primes the immune system so that subsequent insults elicit amplified responses (Rubin and Coons, 1972) .
In the present study, the role of TNFa in models of inflammatory orofacial pain was investigated using both wild type mice (WT) and mice with genetic deletion of both TNFa receptors (TNFR1/ R2À/À). Injection of formalin into the lip identified increased nocifensive responses in TNFR1/R2À/À compared to WT mice. A chronic inflammatory TMD model was induced by an initial inflammatory insult given unilaterally into the TMJ. After hypersensitivity completely resolved, a second inflammatory insult was imposed on the colon 3 weeks later that evoked recrudescence of TMJ inflammatory hypersensitivity only in the TNFR1/R2À/À mice. The chronic hypersensitivity continued through the 4-month experimental timeline. Analysis of serum cytokines and chemokines at multiple time points (Baseline, Days 1, 14, and Week 18) identified both increased and decreased levels of several pro-and anti-inflammatory cytokines in TNFR1/R2À/À compared to wild type mice. Several drugs inhibiting the main inflammatory nociceptive signalling pathways during chronic pain were administered to begin characterization of factors contributing to the chronic inflammatory hypersensitivity many months after the initial TMJ inflammatory flare (Sessle, 2011) . Our data suggest an alternate causal feed-forward signalling cascade causes recrudescence in this orofacial inflammatory pain model in the absence of TNFa signalling.
Materials and methods

Animals
All procedures were approved by the University of Kentucky Institutional Animal Care and Use Committee and followed Guidelines of the National Institutes of Health, the International and the American Pain Associations. Adult male and female mice were housed on a reverse light cycle and given water and food ad libitum. TNFR1/R2À/À animals (B6.129S-Tnfrsf1a tm1/mx Tnfrsf1b tm1/mx /J) were bred in house after purchase of 2 breeding pairs (Jackson Laboratory, Bar Harbor, ME, USA). WT control animals (B6129SF2/J) were ordered directly (Jackson Laboratory). The ovarian hormone cycle of female mice was not tested in this study. A total of 60 mice were tested.
Induction of chronic inflammation: inflammatory 'double hit' model
The inflammatory double hit model (Fig. 1A) is induced with two consecutive inflammatory insults spaced 3 weeks apart. Six female and 8 male TNFR1/ R2À/À and six female and seven male WT mice were tested. The first insult is to the TMJ and the second to the colon, to model clinical reports that rheumatoid arthritis is associated with the presence and changes in colonic bacteria (Klineberg et al., 1998; Chen et al., 2002; Toivanen, 2003) . Recrudescence of hypersensitivity and unilateral swelling occurred 3 weeks after mice were given the 'second hit' and persisted through the 18 week experimental time course.
'First hit'
Animals were lightly anaesthetized with 2% isoflurane inhalation. The right TMJ was injected with 10 lL complete Freund's adjuvant (CFA) emulsion (1 mg/mL heat killed, desiccated Mycobacterium tuberculosis H37 (Sigma, St. Louis, MO, USA) dissolved in sterile saline mixed 1:1 with peanut oil). Similar to our previous study (Westlund et al., 2012) , CFA produced temporary inflammation and pain-like behaviours in both WT and TNFR1/R2À/À mice with recovery within 2 weeks.
'Second hit'
Three weeks after the first insult, animals were again lightly anaesthetized with 2% isoflurane inhalation. Petroleum jelly was applied to the perianal area and a soft, perforated polyethylene tube (PE 90, 1.27 mm diameter) with a blunt, bulbous tip was inserted into the colon (4 cm length). Colonic mustard oil (MO) infusion (50 lL, 0.5% in peanut oil, Sigma-Aldrich, St. Louis, MO, USA) was administered using a syringe connected to the tubing (Lu and Westlund, 2001 ). The tube was removed after 5 min and animals returned to their home cage.
Behavioural assays
For all behavioural experiments, animals were acclimated to the testing room in their home cage for 1 h. Baseline testing for mechanical threshold occurred daily for 1 week prior to experimental start and one day prior to drug tests. All animals were tested at least once a week throughout the experiment, and were tested on days 1, 3, 5, 7, 10, and 14 after the 'First hit'. Three weeks after the 'Second hit' when a spontaneous recrudescence of mechanical hypersensitivity occurred, the animals were tested once 24 h prior to drug treatments and at multiple time points afterwards to determine drug efficacy. The short-lived effect of the drugs allowed testing of a different drug each week since behavioural tests 24 h prior to a drug treatment evidenced return to the reduced threshold indicating that the drugs did not have additive effects. The experiment was conducted in two cohorts using the Latin squares design alternating the sequence of drugs randomly. Results were pooled since no differences were noted between the cohorts.
Head withdrawal mechanical threshold
Mechanical sensitivity was determined by probing the area of the face directly overlaying the TMJ with von Frey filaments to determine the withdrawal threshold using a modified up-down method (Chaplan et al., 1994) . The animal was gently restrained in a tapered plastic bag so that only its head protruded for testing. Head withdrawal threshold was determined using a series of 8 von Frey filaments with logarithmically incremental bending force or stiffness (1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 15.0, 26 .0 g) (Stoelting Co., Wood Dale, IL, USA). A monofilament was applied 3 times perpendicular to skin over the TMJ. If the animal responded (head withdrawal) then a filament of lesser force was used. In case of a negative response, a filament exerting higher force was tested until the mechanical sensitivity threshold was determined.
Heat response latency
Referred heat sensitivity was tested using a hot plate analgesia meter (Columbus Instruments, Columbus, OH). The heated surface (25.4 9 25.4 cm) was held constant at 52°C in a clear acrylic chamber (height: 28 cm) (Zimmer et al., 1999) . The mouse was placed on the surface and the time until a response (hindpaw shaking, licking, jumping, etc.) was measured. Upon response, the animal was immediately removed and returned to its home cage. If an animal did not respond within 30 s (cut-off time), it was removed to prevent tissue damage. This was never noted. Each measurement consisted of 3 trials at 20 min intervals, and the averaged response latency is reported.
Orofacial formalin test
Animal behaviours were recorded with a computer controlled video camera. Baseline behaviour was recorded for 10 min. Animals were gently restrained while 20 lL formalin (5% in 0.9% saline) was injected into the upper right lip with a syringe and 27-gauge needle (Gonzalez et al., 2011) . Mice were immediately returned to the clear cage (29.5 9 18.8 9 13 cm) and behaviours videotaped for 45 min in the absence of a human observer. The data were analyzed offline by an investigator blinded to experimental groups. By literature consensus, the formalin response is characterized in distinct phases. Phase 1 lasts from 0 until 6 min after formalin injection. The quiescent interphase during which animals showed no pain related behaviours lasts from minute 6 until 15 post injection. Phase 2 extends from minute 15 until 45 min post formalin injection. Statistical comparison of the responses during the two phases was done using a non-parametric KruskalWallis with Dunn's post hoc test.
Chemokine/cytokine analysis
Analysis of serum cytokines and chemokines at multiple time points was done in male mice to identify both increased and decreased levels of several pro-and anti-inflammatory cytokines in TNFR1/R2À/À for comparison to wild type mice. On Days 1, 14, and Week 18 (n = 3/group), groups of mice were deeply anesthetized, and blood was collected transcardially into microtainer tubes (BD Diagnostics, Franklin Lakes, NJ, USA). Samples were kept on ice for 60 min to allow clotting, centrifuged at 5000 g for 5 min, and the serum stored at À80°C for analysis. The Proteome Profiler mouse cytokine array Panel A Kit (#ARY006, R&D Systems, Minneapolis, MN, USA) was used to quantify 40 different cyto-and chemokines simultaneously by membrane-based dot blot following manufacturer's instructions. Digitalized radiographic films were analyzed using ImageJ software (NIH, Bethesda, MD) and values expressed as relative pixel density.
Drugs
The efficacy of several different compounds to decrease the recrudesced hypersensitivity was determined in weeks 7-18 after the second insult. The compounds antagonizing cytokines, radical oxygen species, or ion channels were purchased from Tocris (Bristol, UK) unless otherwise stated. For injections, the drugs were dissolved in sterile 0.9% saline. The TNFa neutralizing fusion protein etanercept (Enbrel â ) consisting of the human TNFR2 receptor fused to the Fc (constant) end of the immunoglobulin G1 antibody (Peppel et al., 1991) was injected intraperitoneally (i.p.; 5 mg/kg bodyweight) (Pierno et al., 2007; Malleo et al., 2008) . The unspecific reactive oxygen species (ROS) scavenger alpha-phenyl-N-tert-butyl nitrone (PBN; Sigma) was administered intraperitoneally (i.p.) (100 mg/kg) (Schwartz et al., 2008) or in a separate experiment directly into the TMJ (100 mg/kg in 10 lL). The TRPV1 antagonist capsazepine was injected into the TMJ (10 mg/ kg in 5 lL) (Liang et al., 2007) . The selective noncompetitive NMDA receptor antagonist MK-801 maleate was injected into the TMJ (10 lg/kg in 10 lL) (Du et al., 2003) . The P2X7 antagonist A438079 was injected directly into the TMJ (10 mg/kg in 10 lL).
Statistical analysis
All data are reported as mean AE standard error of the mean (SEM) and compared using non-parametric tests (Friedman or Kruskal-Wallis tests) followed by Dunn's Multiple Comparison Test or Mann-Whitney test using GraphPad Prism Software (San Diego, CA, USA). A p value of less than 0.05 was considered significant.
Results
Inflammatory 'double hit' model
Baseline mechanical withdrawal thresholds were similar in animals of both genetic strains ( Fig. 1B ; WT: 22.6 AE 0.9 g; TNFR1/R2À/À: 22.6 AE 0.9 g).
Unilateral injection of CFA into the TMJ significantly reduced the ipsilateral head withdrawal threshold from baseline in both animal strains to 6.8 AE 0.3 g in wild type and 6.1 AE 0.1 g in TNFR1/R2À/À animals (Fig. 1B , baseline vs. d1, p < 0.005, KruskalWallis test with Dunn's multiple comparison post hoc test). Mechanical sensitivity on the contralateral side was not different from baseline (WT: 21.6 AE 0.9 g; TNFR1/R2À/À: 23.5 AE 0.1 g). Reduction of head withdrawal threshold was maximal on day 1 post injection and returned to baseline levels 5 days after injection. Incomplete Freud's Adjuvant did not induce any behavioural changes.
Heat sensitivity testing determined with a hotplate analgesia meter setting of 52°C was not different between wild type (18.3 AE 0.1 s) and TNFR1/R2À/À (18.6 AE 0.2 s) at baseline. One day after unilateral CFA injection response latencies were significantly reduced compared to baseline in both strains (WT: 11.0 AE 0.3; TNFR1/R2À/À: 11.7 AE 0.6 s; baseline versus d1, p < 0.005, Kruskal-Wallis test with Dunn's multiple comparison post hoc test) and returned to baseline on day 5 (Fig. 1C) .
On day 21 after the CFA injection when mechanical and heat hypersensitivity were resolved, the 'second hit' inflammatory colon insult was induced by infusing a 0.5% mustard oil (MO) solution into the colon for 5 min. Recrudescence of both mechanical and heat hypersensitivity occurred only in the TNFR1/R2À/À after mice given the 'second hit'. Three weeks after MO infusion recrudescence included a statistically significant decrease in mechanical withdrawal thresholds and response latencies in the hotplate analgesia meter, only in the TNFR1/ R2À/À mice. The recrudesced hypersensitivity was maintained chronically (at least through 18 weeks) while thresholds were unchanged from baseline in wild type animals ( Fig. 1D and E) . Several different compounds were tested between weeks 7 and 18 to identify contributing cellular and molecular mechanisms for recrudescence in the TNFR1/R2À/À mice.
Orofacial formalin test
During both Phase 1 and 2 of the formalin test, TNFR1/R2À/À mice displayed significantly increased nocifensive behaviour (wiping and scratching the face, jumping, freezing) compared to wild types (Fig. 2) , while the overall response curve time course was not different between the two strains.
The Phase 1 nocifensive response (0-6 min) peaked during the first 3 min after injection. TNFR1/ R2À/À mice spent 64.4% of this time (231 AE 18.2 s) in nocifensive behaviours while wild type mice spent only 38.3% (138 AE 16.9 s, p < 0.05, Mann-Whitney test). Phase 2 followed after a 9 min quiescent interphase during which animal behaviours were similar to baseline. Phase 2 (15-45 min) lasted through the end of the 45 min experiment and did not return to the original baseline. During Phase 2 TNFR1/R2À/À mice spent 46.3% of this time (888 AE 97.2 s) in nocifensive behaviour while wild types spent only 30.5% (585 AE 36.8 s, p < 0.05, Mann-Whitney test). The TNFR1/R2À/À mice had freezing behaviour and jumped during both phases trying to escape the experimental cage.
Cytokine/chemokine proteome profiles
Serum cytokine and chemokine profiles were determined for na€ ıve male WT and TNFR1/R2À/À mice, as well as for both genotypes 1 and 14 days post CFA injection and at experimental end, 18 weeks post colonic MO instillation ( Fig. 3 and Supporting Information Fig. S1 ).
Initial na€ ıve levels
In na€ ıve TNFR1/R2À/À animals, serum levels of TNFa were twice as high compared to na€ ıve wild type animals. Also in na€ ıve TNFR1/R2À/À animals, chemokine (C-X-C motif) ligand 12 (CXCL12 [SDF-1]), interleukin-1a (IL-1a), IL-7, and IL-17 were elevated while chemokine (C-C motif) ligand 2 (CCL2 [MCP-1, JE]), CXCL1 (KC, NAP-3), and IL-13 were decreased compared to na€ ıve wild type mice. All other inflammatory mediators tested were not different.
3.3.2 Cytokine/chemokine levels increased more than in na€ ıve mice Day 1 levels: Of note, CCL2 was elevated in TNFR1/ R2À/À animals compared to wild types. Recovery Day 14 levels: At day 14 post CFA injection when no behavioural hypersensitivity was detected, high levels of several proinflammatory mediators were detected the TNFR1/R2À/À animals including TNFa, CCL-2, CCL5 (RANTES), CXCL9 (MIG) and CXCL10 (IP-10) compared to WT mice (Fig. 3A) . Week 18 levels: While CXCL9 remained elevated in TNFR1/R2À/À animals at experiment end, the other cytokines returned to basal levels, similar to those in wild type animals.
3.3.3 Cytokine/chemokine levels increased less than in na€ ıve mice 3.3.3.1 Day 1 levels. Acute inflammation on Day 1 induced less increase of 12 of the 40 cytokines in serum from TNFR1/R2À/À animals than in WT mice. One-third of these inflammatory mediators were antiinflammatory such as the haematopoetic factor granulocyte colony-stimulating factor (G-CSF), IL-1ra, IL-4, and tissue inhibitor of matrix metalloproteases-1 (TIMP-1). Other decreased pro-inflammatory mediators included IL-1a, IL-1b, IL-3, CXCL1 (KC, NAP-3), CXCL12 (SDF-1), and triggering receptor expressed on myeloid cells-1 (TREM-1) compared to WT mice ( Fig. 3B and C) . At experiment end, expression of most of these cytokines/chemokines had returned to basal levels in animals of both genotypes.
3.3.3.2 Recovery day 14 levels. CXCL12 in TNFR1/R2À/À animals remained lower than levels in WT mice at all post inflammation time points.
3.3.3.3 Week 18 levels. Several cytokine/chemokine levels were much lower in TNFR1/R2À/À animals than in WT mice, including anti-inflammatory IL1ra, G-CSF, IL-1b, IL-4. genotypes (Supporting Information Fig. S1 ). Expression of CCL1 (I-309), CCL11 (eotaxin), IL-2, IL-10, IL-23, IL-27, CCL3 (MIP-1a), CCL4 (MIP1b), and CXCL2 (MIP-2) in serum did not change during the experiment and was not different in WT and TNFR1/R2À/À animals (data not shown).
Ten of the 40 inflammatory mediators tested had similar time course profiles in both genotypes. IL-17 was the only cytokine identified with initially similar concentrations in both genotypes that had decreased expression during the experiment in both genotypes (data not shown). The expression of IL-5, IL-6 and IL-12p was not detected in our samples in either genotype.
Systemic TNFa antagonist reverses mechanical but not heat hypersensitivity
To determine if increased levels of circulating TNFa contribute to recrudesced hypersensitivity in the TNFR1/R2À/À mice, we administered a single dose of etanercept. One day prior to administration of the TNFa neutralizing antibody both male and female TNFR1/R2À/À mice had significantly reduced mechanical (female: 8.6 AE 0.7 g; male: 11.4 AE 1.8 g; Fig. 4A ) compared to wild type mice (female: 22.9 AE 0.6 g; male: 23.0 AE 0.5 g) ipsilateral to the 'first hit' CFA injection. Thirty minutes after etanercept injection the mechanical thresholds significantly increased to baseline levels in both male and female TNFR1/R2À/À mice (female: 20.1 AE 2.2 s; male: 21.4 AE 1.5 s, p < 0.05, KruskalWallis tests with Dunn's post hoc test) and remained elevated for 3 h (female: 19.0 AE 2.3 g; male: 18.7 AE 2.1 g, p < 0.05, Kruskal-Wallis tests with Dunn's post hoc test). One day after the single dose etanercept treatment mechanical head withdrawal thresholds returned to decreased hypersensitive levels (female: 8.9 AE 1.0 g; male: 9.1 AE 1.3 g). Mechanical withdrawal thresholds of wild type mice were not altered by etanercept and remained at baseline levels. Head withdrawal thresholds on the contralateral side were not decreased by the low dose CFA injection and treatment with etanercept did not alter them (Supporting Information Fig. S2 ). Response latencies to 52°C heat were not significantly improved by treatment with etanercept (TNFR1/R2À/À female: 10.7 AE 0.3 s; male: 10.7 AE 0.4 s 24 h prior to treatment; female: 11.9 AE 0.4 s; male: 12.8 AE 0.7 s 30 min post treatment; Fig. 4B ). No differences between male and female animals were determined.
Systemic and local treatment with radical oxygen species scavenger reduces mechanical hypersensitivity
Numerous studies using acute and persistent models inflammatory nociception have reported increased concentrations of free. Here, the unspecific ROS scavenger PBN was used to determine their contribution to hypersensitivity in the inflammatory double hit model. Systemic injection of PBN resulted in temporarily significantly increased mechanical withdrawal thresholds in both male and female TNFR1/R2À/À mice (p < 0.001, two-way ANOVA with Bonferroni post hoc test). Within 30 min post injection mechanical thresholds significantly increased from 9.1 AE 0.4 g in female and 11.1 AE 2.3 g in male TNFR1/R2À/À mice to 21.9 AE 1.6 g and 21.9 AE 1.5 g, respectively (p < 0.01, Kruskal-Wallis test with Dunn's post hoc test) and returned to the hypersensitive state within 3 h post injection (Fig. 4C) . Single local injections of PBN directly into the ipsilateral TMJ were similarly effective in acutely reducing mechanical hypersensitivity 30 min post injection but did not persist (Fig. 4E) . Unlike the systemic administration, injections into the TMJ showed a better trend to improved mechanical sensitivity in male than in female mice (male: 23.5 AE 0.1 g; female: 19.4 AE 2.3 g; p < 0.05, Kruskal-Wallis test with Dunn's post hoc test). PBN did not alter mechanical sensitivity on the contralateral side (data not shown). Response latencies on the hotplate test were not improved either after systemic PBN treatment (TNFR1/ R2À/À female: 14.2 AE 0.8 s; male: 14.9 AE 0.5 s; Fig. 4D ) or after local TMJ injections (TNFR1/R2À/À female: 10.8 AE 0.7 s; male: 13.7 AE 0.6 s; Fig. 4F ).
P2X7 and NMDA receptor antagonists improve mechanical and heat sensitivity while TRPV1 antagonists improves neither
Several different ion channels were investigated that have been shown to be localized either on peripheral immune cells and/or axonal terminals of nociceptive sensory neurons. Local injection of the selective P2X7 antagonist A438079 into the ipsilateral TMJ briefly reversed mechanical hypersensitivity (TNFR1/ R2À/À female: 19.9 AE 1.8 g; male: 20.7 AE 1.0 g; p < 0.01, Kruskal-Wallis test with Dunn's post hoc test; Fig. 5A ) as well as improved heat hypersensitivity 30 min post injection (TNFR1/R2À/À female: 17.8 AE 0.4 s; male: 16.6 AE 0.5 s; p < 0.01, KruskalWallis test with Dunn's post hoc test; Fig. 5B ), but did not persist. Injection of the NMDA specific antagonist MK801 into the TMJ significantly improved mechanical hypersensitivity within 30 min (TNFR1/ R2À/À female: 19.7 AE 0.6 g; male: 20.4 AE 1.6 s; p < 0.01, Kruskal-Wallis test with Dunn's post hoc test; Fig. 5C ) and persisted for 3 h (TNFR1/R2À/À female: 19.0 AE 0.9 g; male: 16.9 AE 2.2 g). Heat sensitivity was only alleviated 30 min post injection (TNFR1/R2À/À female: 14.8 AE 0.3 s; male: 14.6 AE 0.6 s; 3 h post injection; p < 0.01, Kruskal-Wallis test with Dunn's post hoc test; Fig. 5D ). Use of the TRPV1 antagonist capsazepine did not reduce either mechanical (Fig. 5E ) or heat sensitivity (Fig. 5F ).
Discussion
The data presented demonstrate that unilateral chronic TMJ inflammation could be initiated in TNFR1/R2À/À mice when a 'first hit' TMJ inflammatory insult with CFA was followed later by a mild gastrointestinal inflammation 'second hit' using MO. The 'double hit' model in wild type mice did not induce recrudescence of TMJ inflammation and associated hypersensitivity. In TNFR1/R2À/À mice, the chronic hypersensitivity continued through the 4-month experimental timeline. Cytokine levels of TNFa and several other pro-inflammatory cytokines were increased while several anti-inflammatory cytokines were decreased in blood serum samples of TNFR1/R2À/À mice compared to wild type mice. This was particularly striking on day 14 after CFA injection when behavioural hypersensitivity in animals of both genotypes was recovered. ROS scavenger PBN and TNFa neutralizing fusion protein etanercept, as well as specific antagonists for P2X7 and NMDA receptors were able to attenuate behavioural hypersensitivity while TRPV1 antagonist capsazepine had no effect. These data demonstrate the complexity of molecular signalling pathways involved in the chronic TMJ inflammation. We also determined that TNFR1/R2À/À mice respond to acute inflammation induced by formalin injection into the lip with increased nocifensive behaviour during both phases compared to WT animals. TNFR1/R2À/À mice not only showed wiping and scratching of the injected side of the face, but also responded by freezing and unlike WT mice, jumped to escape the cage. This was unexpected as previous studies reported the absence of functional TNFR1/R2 by use of antibodies or knockout mice to be protective in the formalin test (Seadi Pereira et al., 2009; Zhang et al., 2011a Zhang et al., ,2011b . A possible explanation is differences in experienced environmental stress that reportedly alters susceptibility to arthritis model induction (Ji et al., 2002) . Most recently, a feature in Science magazine attributed differences in gut microbiota to reproducibility differences in published experimental results even when using the identical mouse strain purchased from the same vendor (Servick, 2016) .
The 'double hit' inflammatory insult model produced recrudescence of mechanical hypersensitivity only in the ipsilateral TMJ area injected with the CFA similar to our study using the 'double hit' inflammatory model to model knee joint arthritis (Westlund et al., 2012) . Behavioural hypersensitivity re-occurred weeks after gastrointestinal inflammation only in TNFR1/R2À/À mice while WT animals fully recovered from both insults. The use of CFA to model RA as well as persistent TMJ inflammation is well-established, inducing oedema in the joint and behavioural hypersensitivity (Spears et al., 2003) , symptoms similar to clinical patients (Arthritis Foundation, http://www.arthritis.org). On a technical note, similar to a previous study, we tested the area over the TMJ with von Frey filaments (do Val et al., 2014) . In our experiments, the stimulated skin and underlying tissue was relatively insensitive, requiring higher strength von Frey filaments to elicit a response compared to the whiskerpad and feet. We tested heat sensitivity using the hotplate, demonstrating whole body heat hypersensitivity. A recent publication demonstrated that that orofacial pain induces widespread pain sensitization in rodent models (Zhang et al., 2016) . That study also reported paradoxical mechanical allodynia in the hindpaw with concurrent heat hyperalgesia. Several clinical studies on patients with RA have reported finding gut residing bacteria, cell walls, and their DNA within inflamed joints and to actively drive disease progression (Klineberg et al., 1998; Toivanen, 2001; Chen et al., 2002) . Experimental animal studies have been able to model this for more detailed investigation (Wu et al., 2010) . To model this, the present study used a mild colonic insult with MO as the 'second hit'. We previously demonstrated resolution within 4-8 h of the induced colonic ulceration and cFOS activation in the spinal cord using a higher dose of mustard oil in rats (Lu and Westlund, 2001) . The colonic injection of MO may have interrupted the neuroimmune interactions in the gut and altered circulating microbial metabolites (Holzer et al., 2015) . The combination of the 'double hit' inflammatory insults with hereditary dysregulation of TNFa in TNFR1/R2À/À mice produced a model of chronic TMJ hypersensitivity and altered serum cytokine profiles that characterize a suitable model of TMD. However, future studies are needed to determine if the 'double hit' inflammatory model can also be induced in single TNFR knockout mice and to further characterize the role of the two TNFRs in chronic inflammatory pain.
Time course analysis of 40 mixed anti-and proinflammatory cyto-/chemokines identified differential expression in animals of both genotypes. Approximately ¼ of the analyzed pro-inflammatory cytokines increased after acute inflammation with CFA and then decreased to basal levels in TNFR1/ R2À/À and WT mice. Cyto-/chemokine levels that returned to basal conditions in the WT mice prevented the development of chronic inflammation. In TNFR1/R2À/À mice several pro-inflammatory cytokines, TNFa, CCL2, CXCL9, CXCL10 and RANTES were elevated compared to WT animals. Levels of TNFa were increased threefold compared to WTs, similar to previous studies (Peschon et al., 1998; Westlund et al., 2012) . Typically, TNFa signalling is pro-inflammatory and its inhibition decreases inflammation (Kopp et al., 2005 ). Yet, several reports have shown that it also initiates the release of anti-inflammatory cytokines, those decreasing inflammation. TNFa signalling has been shown to inhibit IL-12 and IL-23 in macrophages and dendritic cells (Zakharova and Ziegler, 2005) . Tolerance and secretion of IL-12 of transforming growth factor beta (TGF-b) activated antigen-presenting cells in the eye is negatively regulated by TNFa, resulting in a decreased immune response (Masli and Turpie, 2009) .
Elevated concentrations of CCL2, CXCL9, CXCL10 and RANTES in the synovial tissue and blood serum of patients diagnosed with RA and chronic TMJ inflammation have all been extensively described in the literature. Patient serum levels of CCL2, CXCL9 and CXCL10 correlate with severity of RA progression, and have been used to monitor efficacy of novel RA treatments (Konig et al., 2000; Shah et al., 2011; Xia et al., 2011) . Their increased levels in our 'double hit' inflammatory model in TNFR1/R2À/À mice only indicates that in the absence of TNFa their levels are dysregulated, though their up-regulation is supportive of the relevance of the 'double-hit' model described here. Similar findings and correlation of pain scores with selected cytokines are reported in collagen induced hindpaw arthritis (Kagari et al., 2002) . Concurrent decreased levels of anti-inflammatory IL-1ra and IL-4 were measured in TNFR1/ R2À/À mice that remained lower than in WT animals until experimental end. Elevated levels of IL1ra in clinical patients have been measured in the TMJ of patients with polyarthritis who reported minimal amounts of pain (Alstergren et al., 2003; Kopp et al., 2005) . Treatment with recombinant human IL-1ra was shown to not only decrease cartilage but to facilitate cartilage repair degradation in experimentally induced arthritis in the TMJ (Zhang et al., 2011a; Zhang et al., 2011b) . These data suggest that the combination of elevated levels of CCL2, CXCL9, CXCL10 and RANTES combined with decreases of anti-inflammatory IL-1ra and IL-4 may have contributed to chronic inflammation in the TMJ and behavioural hypersensitivity in the TNFR1/R2À/À mice. Surprisingly, use of etanercept reduced mechanical hypersensitivity in TNFR1/R2À/À mice. It has been repeatedly demonstrated in the last 20 years that TNFa specifically binds the TNFR1 and TNFR2 receptors (Beutler and van Huffel, 1994; Locksley et al., 2001) . No other receptor bindings have so far been demonstrated for TNFa. In the absence of both TNFa receptors, even threefold increased levels over WT animals are unable to initiate any signalling cascades. Etanercept is a unique biological in that it is a human fusion protein consisting of the TNFR2 receptor and the IgG heavy chain (Peppel et al., 1991) . It is unclear if the ability of etanercept to reduce hypersensitivity briefly in TNFR1/R2À/À mice during chronic inflammation was due to neutralization of LTa since etanercept not only binds TNFa but also LTa (Beutler and van Huffel, 1994; Locksley et al., 2001) . In any event, a short efficacy is noted in mice with this human protein in the present study and in others (Christianson et al., 2010; Park et al., 2013) .
Several limitations can be noted in this study. Limitations imposed by the breeding colony did not allow completion of all testing in both male and female mice. Formalin and cytokine analysis was only performed in male mice. While ovarian hormone cycling information was not collected in the female mice, we did not find sex differences in mechanical and heat sensitivity in the 'double hit' TMJ chronic inflammation model. Gender differences in orofacial pain signalling and incidence in clinical patients have been reported (Warren and Fried, 2001; Gazerani et al., 2010) . We utilized von Frey filaments, a well-established method, that required of the animal's movements in order to determine mechanical withdrawal thresholds by stimulation the area of the face overlaying the TMJ without touching the highly sensitive sinus hairs located in close proximity. It is therefore possible that stress caused by gentle restraint differed between male and female animals, overshadowing gender differences of hypersensitivity.
We also investigated peripheral tissue mechanisms for their contribution to maintenance of chronic pain. Clinical studies have identified several genes encoding ion channels and receptors with single nucleotide polymorphisms (SNPs) expressed by local immune cells, neurons and glia that alter the susceptibility for chronic pain (Lacroix-Fralish and Mogil, 2009) . Acute local inhibition of P2X7 and NMDA receptors was able to normalize both mechanical and heat sensitivity. Both compounds are able to decrease peripheral sensory neuron activity either indirectly or directly, thus reducing mechanical hypersensitivity tested by applying force directly over the TMJ (Gazerani et al., 2010; Arandjelovic et al., 2012) .
The P2X7 purinergic receptor is localized on immune and trigeminal ganglia satellite glial cells, suggesting that its inhibition may have decreased the release of excitatory molecules onto nociceptors, thus reducing behavioural hypersensitivity to noxious stimuli (Donnelly-Roberts and Jarvis, 2007; Kushnir et al., 2011) . The P2X7 ion channel is expressed on mast cells and use of the antagonist may have decreased inflammatory signalling cascades initiated by ATP that result in mast cell activation (Arandjelovic et al., 2012) . Treatment with A438079 may have also decreased local levels of pro-inflammatory cytokines IL-1b and IL-18, thus decreasing immune-neural interactions resulting in decreased hypersensitivity (McGaraughty et al., 2007) .
Glutamate is released by damaged cells as well as by primary sensory neurons innervating the tissue (deGroot et al., 2000) and activates neurons by binding to both ionotropic and metabotropic receptors. The NMDA receptor is localized on primary afferents innervating the TMJ as well as peripheral immune cells (Gazerani et al., 2010) . After peripheral nerve injury, increased expression of the NMDA receptor in DRG neurons has been correlated with an influx of immune cells into the injury site, behavioural hypersensitivity, and an increase of activated microglia in the spinal cord, suggesting a role for glutamate and the NMDA receptor in peripheral and central neuroimmune responses (Gazerani et al., 2010) . Our data demonstrate that MK801 efficaciously decreased mechanical and heat hypersensitivity. While the exact mechanisms are still being elucidated, it is known that both antagonists initiate different second messenger signalling cascades and have different efficacy in reducing nociceptive responses after injury (Suzuki et al., 2001) . The data presented suggest involvement of the NMDA receptor maintaining hypersensitivity produced by the 'double hit' inflammatory insult.
Afferents expressing TRPV1 have been reported to have an essential role in establishing inflammatory heat hypersensitivity, yet, our data similar to others suggest that it is not essential to transduce noxious heat stimuli chronically (Woodbury et al., 2004) . In the present study, only the effect of local capsazepine application was tested. It is therefore possible that its systemic use might reduce chronic inflammation induced hypersensitivity.
Cellular stress and damage cause the production and release of ROS, which combined with an imbalance of pro-and anti-inflammatory cytokines are universal biomarkers of inflammatory diseases including RA and chronic inflammation of the TMJ (Thacker et al., 2007) . We have previously shown ROS increase in the spinal cord in a knee joint arthritis model, as well as secondary mechanical and heat sensitization that is ameliorated with the ROS scavenger PBN (Westlund et al., 2010) . A recent study demonstrated a positive correlation between levels of ROS and pro-inflammatory cytokines CCL2, CXCL10 and RANTES (Shah et al., 2011) , speculating that these molecules act in a positive feed-forward loop. Our data identified a contribution of an altered redox status in TNFR1/R2À/À mice with chronic inflammation as use of the ROS scavenger PBN was able to normalize mechanical hypersensitivity acutely.
The data presented here identify several different pro-inflammatory systems that act in concert in a feed-forward mechanism in the 'double hit' inflammatory model. The chronic inflammation and hypersensitivity produced long term in these animals with hereditary dysregulated TNFa signalling identifying them as novel targets for pharmacological interventions. 
